{"protocolSection": {"identificationModule": {"nctId": "NCT01103284", "orgStudyIdInfo": {"id": "DiaPep277-1001"}, "organization": {"fullName": "Andromeda Biotech Ltd.", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults", "officialTitle": "A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Clinical Efficacy and Safety of DiaPep277 in Newly Diagnosed Type 1 Diabetes Subjects", "acronym": "DIA-AID2"}, "statusModule": {"statusVerifiedDate": "2016-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-04"}, "primaryCompletionDateStruct": {"date": "2014-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-04-13", "studyFirstSubmitQcDate": "2010-04-13", "studyFirstPostDateStruct": {"date": "2010-04-14", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-11-16", "resultsFirstSubmitQcDate": "2016-04-19", "resultsFirstPostDateStruct": {"date": "2016-05-26", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-04-19", "lastUpdatePostDateStruct": {"date": "2016-05-26", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Andromeda Biotech Ltd.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "This study will look at the treatment effect of DiaPep277 on preservation of beta-cell function, as defined by meal-stimulated secretion of insulin. DiaPep277 is a peptide that changes the way the immune system behaves, stopping its attack on the beta-cells.\n\nAdults (\\>20 years) with newly diagnosed (\\<6 months) type 1 diabetes will be treated with 10 injections of DiaPep277 or Placebo over a 2-year treatment and follow-up period."}, "conditionsModule": {"conditions": ["Type 1 Diabetes Mellitus"], "keywords": ["beta-cells", "autoimmune", "Diabetes", "immunomodulation"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 475, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "DiaPep277", "type": "EXPERIMENTAL", "description": "Administration of 1 mg DiaPep277\u00ae, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.", "interventionNames": ["Drug: DiaPep277"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Administration of placebo, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "DiaPep277", "description": "1.0 mg dose in 0.5 mL of solution", "armGroupLabels": ["DiaPep277"]}, {"type": "DRUG", "name": "Placebo", "description": "40 mg mannitol in 0.5 mL of solution.\n\nDosing: 0, 1, 3, 6, 9, 12, 15, 18, 21, 24 months", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Glucagon-Stimulated C-Peptide AUC at 24 Months", "description": "Change in Beta-cell function, measured as stimulated C-peptide secretion 0, 2, 6, 10 and 20 minutes post administration \\[area under the curve (AUC), 0-20 minutes\\] at baseline and 24 months, during a glucagon stimulation test (GST). The change in AUC was calculated per patient by subtracting the baseline AUC from the 24 month AUC.", "timeFrame": "Baseline and 24 months"}], "secondaryOutcomes": [{"measure": "Percentage of Subjects That Achieve Good Glycemic Control: HbA1c<7%", "description": "The percentage of subjects achieving good glycemic control, i.e. an HbA1c \\<7% at study end (Month 25). If HbA1c was missing at Month 25, but the Month 24 value was available, then the Month 24 value was used to calculate the percentage of subjects with an HbA1c \u2264 7% at study end.", "timeFrame": "24 and 25 months"}, {"measure": "Frequency of Hypoglycemic Events", "description": "Total number of days with at least one hypoglycemic event recorded", "timeFrame": "Baseline to 25 Months"}, {"measure": "Mean Number of Days With at Least One Hypoglycemic Event", "timeFrame": "Baseline to 25 months"}], "otherOutcomes": [{"measure": "Percentage of Subjects Requiring a Daily Insulin Dose \u2264 0.5 IU/kg at End of Study", "description": "Percentage of subjects requiring a daily insulin dose \u2264 0.5 IU/kg at end of study (25 Months). If insulin dose was missing at Month 25, but the Month 24 value was available, then the Month 24 value was used to calculate the percentage of subjects with a daily insulin dose \u2264 0.5 IU/kg at study end.", "timeFrame": "24 and 25 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* clinical diagnosis of type 1 diabetes within last 6 months\n* Age 20-45 years\n* fasting basal C-peptide equal or greater than 0.22 nmol/L, lower than 0.8 nmol/L\n* BMI between 17 and 30 at screening\n\nExclusion Criteria:\n\n* Significant disease or condition other than type 1 diabetes\n* Diabetes-related complications\n* Ongoing treatment with immunosuppressive or immunomodulating agents including chronic corticosteroids", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "20 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Itamar Raz, MD", "affiliation": "Hadassah Medical Center, Jerusalem", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Thomas Linn, MD", "affiliation": "University of Giessen", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Paolo P Pozzilli, MB, BS, MD", "affiliation": "University Campus Bio-Medico, Rome", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Philip Raskin, MD", "affiliation": "UT Southwestern Medical Center, Dallas", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"city": "Los Gatos", "state": "California", "zip": "95032", "country": "United States", "geoPoint": {"lat": 37.22661, "lon": -121.97468}}, {"facility": "Sutter Gold Medical Foundation", "city": "Modesto", "state": "California", "zip": "95355", "country": "United States", "geoPoint": {"lat": 37.6391, "lon": -120.99688}}, {"facility": "San Diego Clinical Trials", "city": "San Diego", "state": "California", "zip": "92120", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "University of Colorado Hospital - Anschutz Outpatient Pavilion", "city": "Aurora", "state": "Colorado", "zip": "80045", "country": "United States", "geoPoint": {"lat": 39.72943, "lon": -104.83192}}, {"facility": "Creekside Endocrine Associates, Inc.", "city": "Denver", "state": "Colorado", "zip": "80209", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "George Washington University Medical Faculty Associates", "city": "Washington", "state": "District of Columbia", "zip": "20037", "country": "United States", "geoPoint": {"lat": 38.89511, "lon": -77.03637}}, {"facility": "Innovative Medical Research of South Florida Inc.", "city": "Aventura", "state": "Florida", "zip": "33180", "country": "United States", "geoPoint": {"lat": 25.95648, "lon": -80.13921}}, {"city": "DeLand", "state": "Florida", "zip": "32720", "country": "United States", "geoPoint": {"lat": 29.02832, "lon": -81.30312}}, {"facility": "Orlando Diabetes & Endocrine Specialists, P.A.", "city": "Orlando", "state": "Florida", "zip": "32825", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "Tallahassee Endocrine Associates", "city": "Tallahassee", "state": "Florida", "zip": "32308", "country": "United States", "geoPoint": {"lat": 30.43826, "lon": -84.28073}}, {"facility": "Diabetes and Hormonal Disease Center", "city": "Tampa", "state": "Florida", "zip": "33613", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "Atlanta Diabetes Associates", "city": "Atlanta", "state": "Georgia", "zip": "30309", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Kentucky Diabetes Endocrinology Center", "city": "Lexington", "state": "Kentucky", "zip": "40503", "country": "United States", "geoPoint": {"lat": 37.98869, "lon": -84.47772}}, {"facility": "Washington University", "city": "St. Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Palm Medical Research Center", "city": "Las Vegas", "state": "Nevada", "zip": "89148", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "Soutwest Clinical Research Center, LLC", "city": "Santa Fe", "state": "New Mexico", "zip": "87505", "country": "United States", "geoPoint": {"lat": 35.68698, "lon": -105.9378}}, {"facility": "Mountain Diabetes and Endocrine Center", "city": "Ashville", "state": "North Carolina", "zip": "28803", "country": "United States", "geoPoint": {"lat": 35.60095, "lon": -82.55402}}, {"facility": "University of North Carolina Diabetes Care Center", "city": "Durham", "state": "North Carolina", "zip": "27703", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "The Lindner Research Center, The Christ Hospital", "city": "Cincinnati", "state": "Ohio", "zip": "45219", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Cleveland Clinic", "city": "Cleveland", "state": "Ohio", "zip": "44195", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "Legacy Clinical Research & Technology Center", "city": "Portland", "state": "Oregon", "zip": "97210", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "AM Diabetes & Endocrinology Center", "city": "Bartlett", "state": "Tennessee", "zip": "38133", "country": "United States", "geoPoint": {"lat": 35.20453, "lon": -89.87398}}, {"facility": "Research Institute of Dallas", "city": "Dallas", "state": "Texas", "zip": "75231", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Cetero Research", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Northside Internal Medicine Associates, PS", "city": "Spokane", "state": "Washington", "zip": "99208", "country": "United States", "geoPoint": {"lat": 47.65966, "lon": -117.42908}}, {"facility": "Multicare Specialties Research", "city": "Tacoma", "state": "Washington", "zip": "98405", "country": "United States", "geoPoint": {"lat": 47.25288, "lon": -122.44429}}, {"facility": "Universitatsklinik fur Innere Medzin I, Landeskrankenhaus", "city": "Innsbruck", "zip": "6020", "country": "Austria", "geoPoint": {"lat": 47.26266, "lon": 11.39454}}, {"facility": "Rudolfstiftung Hospital", "city": "Vienna", "zip": "1030", "country": "Austria", "geoPoint": {"lat": 48.20849, "lon": 16.37208}}, {"facility": "Endocrinological Unit 1st City Clinical Hospital", "city": "Minsk", "zip": "220013", "country": "Belarus", "geoPoint": {"lat": 53.9, "lon": 27.56667}}, {"facility": "Republican center of Medical Rehabilitation and Balneotherapy", "city": "Minsk", "zip": "220013", "country": "Belarus", "geoPoint": {"lat": 53.9, "lon": 27.56667}}, {"facility": "Health Institution City Endocrinological Dispensary", "city": "Minsk", "zip": "220029", "country": "Belarus", "geoPoint": {"lat": 53.9, "lon": 27.56667}}, {"facility": "Belarusian Medical Academy of Postgraduate Education", "city": "Minsk", "zip": "220096", "country": "Belarus", "geoPoint": {"lat": 53.9, "lon": 27.56667}}, {"facility": "Health Institution Mogilev Diagnostic Center", "city": "Mogilov", "zip": "212030", "country": "Belarus"}, {"facility": "LMC Endocrinology Centres", "city": "Calgary", "state": "Alberta", "zip": "T2H 0K2", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "LMC Endocrinology Centres", "city": "Oakville", "state": "Ontario", "zip": "L6H 3P1", "country": "Canada", "geoPoint": {"lat": 43.45011, "lon": -79.68292}}, {"facility": "LMC Endocrinoly Centres", "city": "Toronto", "state": "Ontario", "zip": "M4R 2G4", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Fakultni nemocnice Kralovske Vinohrady - II. internal department", "city": "Prague", "zip": "10035", "country": "Czech Republic", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "IKEM/Diabetes Centre/Videnska", "city": "Prague", "zip": "4140", "country": "Czech Republic", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Tutkimusyksikko", "city": "Oulu", "zip": "90220", "country": "Finland", "geoPoint": {"lat": 65.01236, "lon": 25.46816}}, {"facility": "DDZ Studienzentrum Deutsches Diabetes Zentrum", "city": "Dusseldorf", "zip": "40225", "country": "Germany", "geoPoint": {"lat": 51.22172, "lon": 6.77616}}, {"facility": "Universitatsklinikum Giessen", "city": "Giessen", "zip": "35392", "country": "Germany", "geoPoint": {"lat": 50.58727, "lon": 8.67554}}, {"facility": "Diabetes Centre for Children and Adolescents, Kinderkrankenhaus auf der Bult", "city": "Hannover", "zip": "30173", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"facility": "Institut f\u00fcr Diabetesforschung an der Klinik und Hochschulambulanz f\u00fcr Kinder- und Jugendmedizin", "city": "Munchen", "zip": "80804", "country": "Germany", "geoPoint": {"lat": 48.13743, "lon": 11.57549}}, {"facility": "Institut f\u00fcr Diabetesforschung M\u00fcnster GmbH", "city": "Munster", "zip": "48145", "country": "Germany", "geoPoint": {"lat": 51.96236, "lon": 7.62571}}, {"facility": "University of Szeged Faculty of Medicin", "city": "Szeged", "zip": "H-6700", "country": "Hungary", "geoPoint": {"lat": 46.253, "lon": 20.14824}}, {"facility": "Veszprem Megyei Csolnoky Ferenc Korhaz es Rendelointezet Diabetologia Centrum", "city": "Veszprem", "zip": "8200", "country": "Hungary", "geoPoint": {"lat": 47.09327, "lon": 17.91149}}, {"facility": "Zala Megyei Korhaz es Rendelointezet Diabetologia Centrum", "city": "Zalaegerszeg", "zip": "9000", "country": "Hungary", "geoPoint": {"lat": 46.84, "lon": 16.84389}}, {"facility": "Diabetes Clinic Soroka University", "city": "Beer Sheva", "zip": "84101", "country": "Israel", "geoPoint": {"lat": 31.25181, "lon": 34.7913}}, {"facility": "Soroka University Medical Center", "city": "Beer Sheva", "zip": "84101", "country": "Israel", "geoPoint": {"lat": 31.25181, "lon": 34.7913}}, {"facility": "Rambam Medical Cent", "city": "Haifa", "zip": "31096", "country": "Israel", "geoPoint": {"lat": 32.81841, "lon": 34.9885}}, {"facility": "Wolfson Medical Center", "city": "Holon", "country": "Israel", "geoPoint": {"lat": 32.01034, "lon": 34.77918}}, {"facility": "Hadassah Medical Center", "city": "Jerusalem", "country": "Israel", "geoPoint": {"lat": 31.76904, "lon": 35.21633}}, {"facility": "Institute for Endocrinology and Diabetes Schneider Children's MC", "city": "Petach-Tiqva", "zip": "49202", "country": "Israel", "geoPoint": {"lat": 32.08707, "lon": 34.88747}}, {"facility": ". Endocrinologia e Malattie Metaboliche, Dipartimento biomedico di medicina interna e specialistica, Ex Istituto di clinica medica, Universit\u00e0 di Palerm", "city": "Palermo", "zip": "90127", "country": "Italy", "geoPoint": {"lat": 38.13205, "lon": 13.33561}}, {"facility": "Dept. of Endocrinology and Diabetes University Campus Bio-Medico", "city": "Rome", "zip": "00128", "country": "Italy", "geoPoint": {"lat": 41.89193, "lon": 12.51133}}, {"facility": "University La Sapienza, Policlinico Umberto I", "city": "Rome", "zip": "00161", "country": "Italy", "geoPoint": {"lat": 41.89193, "lon": 12.51133}}, {"facility": "Private Clinic JSC 'Kristavita'", "city": "Jonava", "zip": "55201", "country": "Lithuania", "geoPoint": {"lat": 55.08333, "lon": 24.28333}}, {"facility": "Kaunas Medical University Hospital", "city": "Kaunas", "zip": "50009", "country": "Lithuania", "geoPoint": {"lat": 54.90272, "lon": 23.90961}}, {"facility": "Public Institution 'Seskines Outpatient Clinic'", "city": "Vilnius", "zip": "07156", "country": "Lithuania", "geoPoint": {"lat": 54.68916, "lon": 25.2798}}, {"facility": "Vilnius Medical University Hospital, Santariskiu Clinic's", "city": "Vilnius", "zip": "08661", "country": "Lithuania", "geoPoint": {"lat": 54.68916, "lon": 25.2798}}, {"facility": "NZOZ OmniMed", "city": "Lodz", "zip": "93-338", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "State Educational Institution for Additional Professional Education (SEIAPE) \"Ural State Medical", "city": "Chelyabinsk", "zip": "454021", "country": "Russian Federation", "geoPoint": {"lat": 55.15402, "lon": 61.42915}}, {"facility": "Kemerovo Regional Clinical Hospital", "city": "Kemerovo", "zip": "650066", "country": "Russian Federation", "geoPoint": {"lat": 55.33333, "lon": 86.08333}}, {"facility": "Endocrinological scientific center of Rosmedtechnology", "city": "Moscow", "zip": "117036", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "SEIAPE Endocrinology and Diabetology", "city": "Moscow", "zip": "125367", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "City Clinical Hospital #81, Endocrinology Department", "city": "Moscow", "zip": "127644", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Clinic of New Medical Technology, LLC", "city": "Moscow", "zip": "140091", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "State Healthcare Institution (SHI) \"Nizhegorodskaya", "city": "Nizhni Novgorod", "zip": "603126", "country": "Russian Federation", "geoPoint": {"lat": 56.32867, "lon": 44.00205}}, {"facility": "State Healthcare Institution Perm Region Clinical Hospital", "city": "Perm", "zip": "614990", "country": "Russian Federation", "geoPoint": {"lat": 58.01046, "lon": 56.25017}}, {"facility": "Limited Liability Company (LLC), Diabetes Center", "city": "Samara", "zip": "443067", "country": "Russian Federation", "geoPoint": {"lat": 53.20007, "lon": 50.15}}, {"facility": "State Educational Institution of Higher Professional Education", "city": "St Petersburg", "zip": "197022", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "St. Petersburg State Healthcare Institution", "city": "St. Petersburg", "zip": "194354", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Siberian State Medical University of Roszdrav", "city": "Tomsk", "zip": "634050", "country": "Russian Federation", "geoPoint": {"lat": 56.49771, "lon": 84.97437}}, {"facility": "Complejo Hospitalario Universitario Insular Materno-Infantil", "city": "Las Palmas de Gran Canaria", "zip": "35016", "country": "Spain", "geoPoint": {"lat": 28.09973, "lon": -15.41343}}, {"facility": "Hospital Universitari Arnau de Vilanova", "city": "Lleida", "zip": "25198", "country": "Spain", "geoPoint": {"lat": 41.61674, "lon": 0.62218}}]}, "referencesModule": {"references": [{"pmid": "18422727", "type": "BACKGROUND", "citation": "Huurman VA, van der Meide PE, Duinkerken G, Willemen S, Cohen IR, Elias D, Roep BO. Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes. Clin Exp Immunol. 2008 Jun;152(3):488-97. doi: 10.1111/j.1365-2249.2008.03656.x. Epub 2008 Apr 16."}, {"pmid": "17024692", "type": "BACKGROUND", "citation": "Huurman VA, Decochez K, Mathieu C, Cohen IR, Roep BO. Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev. 2007 May;23(4):269-75. doi: 10.1002/dmrr.691."}, {"pmid": "17103487", "type": "BACKGROUND", "citation": "Schloot NC, Meierhoff G, Lengyel C, Vandorfi G, Takacs J, Panczel P, Barkai L, Madacsy L, Oroszlan T, Kovacs P, Suto G, Battelino T, Hosszufalusi N, Jermendy G. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials. Diabetes Metab Res Rev. 2007 May;23(4):276-85. doi: 10.1002/dmrr.707."}, {"pmid": "17124720", "type": "BACKGROUND", "citation": "Raz I, Avron A, Tamir M, Metzger M, Symer L, Eldor R, Cohen IR, Elias D. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial. Diabetes Metab Res Rev. 2007 May;23(4):292-8. doi: 10.1002/dmrr.712."}, {"pmid": "19267355", "type": "BACKGROUND", "citation": "Eldor R, Kassem S, Raz I. Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results. Diabetes Metab Res Rev. 2009 May;25(4):316-20. doi: 10.1002/dmrr.942."}, {"pmid": "11734230", "type": "BACKGROUND", "citation": "Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet. 2001 Nov 24;358(9295):1749-53. doi: 10.1016/S0140-6736(01)06801-5."}, {"pmid": "17130576", "type": "BACKGROUND", "citation": "Elias D, Avron A, Tamir M, Raz I. DiaPep277 preserves endogenous insulin production by immunomodulation in type 1 diabetes. Ann N Y Acad Sci. 2006 Oct;1079:340-4. doi: 10.1196/annals.1375.052."}, {"pmid": "16893923", "type": "BACKGROUND", "citation": "Nussbaum G, Zanin-Zhorov A, Quintana F, Lider O, Cohen IR. Peptide p277 of HSP60 signals T cells: inhibition of inflammatory chemotaxis. Int Immunol. 2006 Oct;18(10):1413-9. doi: 10.1093/intimm/dxl074. Epub 2006 Aug 7."}, {"pmid": "20034363", "type": "BACKGROUND", "citation": "Fischer B, Elias D, Bretzel RG, Linn T. Immunomodulation with heat shock protein DiaPep277 to preserve beta cell function in type 1 diabetes - an update. Expert Opin Biol Ther. 2010 Feb;10(2):265-72. doi: 10.1517/14712590903555176."}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "Patients newly diagnosed with Type 1 diabetes were recruited at medical centers in the US, EU, Argentina, and Israel.", "groups": [{"id": "FG000", "title": "DiaPep277", "description": "Administration of 1 mg DiaPep277\u00ae, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.\n\nDiaPep277: 1.0 mg dose in 0.5 mL of solution"}, {"id": "FG001", "title": "Placebo", "description": "Administration of placebo, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.\n\nPlacebo: 40 mg mannitol in 0.5 mL of solution.\n\nDosing: 0, 1, 3, 6, 9, 12, 15, 18, 21, 24 months"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "236"}, {"groupId": "FG001", "numSubjects": "239"}]}, {"type": "Treated", "achievements": [{"groupId": "FG000", "numSubjects": "236"}, {"groupId": "FG001", "numSubjects": "238"}]}, {"type": "At Least One Post-baseline Visit (FAS)", "achievements": [{"groupId": "FG000", "comment": "Patients reaching this milestone were included in the Full Analysis Set (FAS) population", "numSubjects": "233"}, {"groupId": "FG001", "comment": "Patients reaching this milestone were included in the Full Analysis Set (FAS)", "numSubjects": "235"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "194"}, {"groupId": "FG001", "numSubjects": "195"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "42"}, {"groupId": "FG001", "numSubjects": "44"}]}], "dropWithdraws": [{"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "10"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "18"}]}, {"type": "Dermal Hypersensitivity", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Termination by the Sponsor", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Not described", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Missing CRF entries for study completion", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All patients randomized into the study are included in presentation of baseline results", "groups": [{"id": "BG000", "title": "DiaPep277", "description": "Administration of 1 mg DiaPep277\u00ae, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.\n\nDiaPep277: 1.0 mg dose in 0.5 mL of solution"}, {"id": "BG001", "title": "Placebo", "description": "Administration of placebo, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.\n\nPlacebo: 40 mg mannitol in 0.5 mL of solution.\n\nDosing: 0, 1, 3, 6, 9, 12, 15, 18, 21, 24 months"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "236"}, {"groupId": "BG001", "value": "238"}, {"groupId": "BG002", "value": "474"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "28.7", "spread": "6.75"}, {"groupId": "BG001", "value": "28.5", "spread": "6.56"}, {"groupId": "BG002", "value": "28.6", "spread": "6.65"}]}]}]}, {"title": "Age, Customized", "paramType": "MEDIAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "27.0", "lowerLimit": "20", "upperLimit": "45"}, {"groupId": "BG001", "value": "27.0", "lowerLimit": "20", "upperLimit": "45"}, {"groupId": "BG002", "value": "27.0", "lowerLimit": "20", "upperLimit": "45"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "79"}, {"groupId": "BG001", "value": "73"}, {"groupId": "BG002", "value": "152"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "157"}, {"groupId": "BG001", "value": "165"}, {"groupId": "BG002", "value": "322"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Caucasian", "categories": [{"measurements": [{"groupId": "BG000", "value": "224"}, {"groupId": "BG001", "value": "225"}, {"groupId": "BG002", "value": "449"}]}]}, {"title": "Hispanic", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "12"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "7"}]}]}, {"title": "Oriental", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}]}]}, {"title": "Unknown", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Daily Insulin Dose", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "IU/kg/day", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.305", "spread": "0.1587"}, {"groupId": "BG001", "value": "0.317", "spread": "0.1649"}, {"groupId": "BG002", "value": "0.311", "spread": "0.1618"}]}]}]}, {"title": "Fasting C-Peptide", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "nmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.388", "spread": "0.1473"}, {"groupId": "BG001", "value": "0.407", "spread": "0.1731"}, {"groupId": "BG002", "value": "0.398", "spread": "0.1609"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Glucagon-Stimulated C-Peptide AUC at 24 Months", "description": "Change in Beta-cell function, measured as stimulated C-peptide secretion 0, 2, 6, 10 and 20 minutes post administration \\[area under the curve (AUC), 0-20 minutes\\] at baseline and 24 months, during a glucagon stimulation test (GST). The change in AUC was calculated per patient by subtracting the baseline AUC from the 24 month AUC.", "populationDescription": "Full Analysis Set (FAS) All subjects randomized who had a baseline visit and at least one scheduled post-baseline visit", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "nmol*min/L", "timeFrame": "Baseline and 24 months", "groups": [{"id": "OG000", "title": "DiaPep277", "description": "Administration of 1 mg DiaPep277\u00ae, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.\n\nDiaPep277: 1.0 mg dose in 0.5 mL of solution"}, {"id": "OG001", "title": "Placebo", "description": "Administration of placebo, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.\n\nPlacebo: 40 mg mannitol in 0.5 mL of solution.\n\nDosing: 0, 1, 3, 6, 9, 12, 15, 18, 21, 24 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "233"}, {"groupId": "OG001", "value": "235"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.20", "spread": "0.27"}, {"groupId": "OG001", "value": "-4.83", "spread": "0.30"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.33", "pValueComment": "The a priori threshold for statistical significance was 0.05", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "The Mixed-Effect Model Repeated Measure (MMRM) was adjusted for the following baseline covariates: age, C-peptide, insulin dose by body weight and AUC"}]}, {"type": "SECONDARY", "title": "Percentage of Subjects That Achieve Good Glycemic Control: HbA1c<7%", "description": "The percentage of subjects achieving good glycemic control, i.e. an HbA1c \\<7% at study end (Month 25). If HbA1c was missing at Month 25, but the Month 24 value was available, then the Month 24 value was used to calculate the percentage of subjects with an HbA1c \u2264 7% at study end.", "populationDescription": "Full Analysis Set (FAS) All subjects randomized who had a baseline visit and at least one scheduled post-baseline visit.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percentage of subjects", "timeFrame": "24 and 25 months", "groups": [{"id": "OG000", "title": "DiaPep277", "description": "Administration of 1 mg DiaPep277\u00ae, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.\n\nDiaPep277: 1.0 mg dose in 0.5 mL of solution"}, {"id": "OG001", "title": "Placebo", "description": "Administration of placebo, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.\n\nPlacebo: 40 mg mannitol in 0.5 mL of solution.\n\nDosing: 0, 1, 3, 6, 9, 12, 15, 18, 21, 24 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "233"}, {"groupId": "OG001", "value": "235"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "47", "lowerLimit": "40", "upperLimit": "54"}, {"groupId": "OG001", "value": "47", "lowerLimit": "40", "upperLimit": "55"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.68", "pValueComment": "A priori threshold for statistical significance was 0.05", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "The MMRM model was adjusted for the following covariates: age, Baseline C-peptide, Baseline insulin dose adjusted for body weight, and Baseline AUC.", "ciNumSides": "TWO_SIDED"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Percentage of Subjects Requiring a Daily Insulin Dose \u2264 0.5 IU/kg at End of Study", "description": "Percentage of subjects requiring a daily insulin dose \u2264 0.5 IU/kg at end of study (25 Months). If insulin dose was missing at Month 25, but the Month 24 value was available, then the Month 24 value was used to calculate the percentage of subjects with a daily insulin dose \u2264 0.5 IU/kg at study end.", "populationDescription": "Full Analysis Set (FAS) All subjects randomized who had a baseline visit and at least one scheduled post-baseline visit.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percentage of subjects", "timeFrame": "24 and 25 months", "groups": [{"id": "OG000", "title": "DiaPep277", "description": "Administration of 1 mg DiaPep277\u00ae, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.\n\nDiaPep277: 1.0 mg dose in 0.5 mL of solution"}, {"id": "OG001", "title": "Placebo", "description": "Administration of placebo, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.\n\nPlacebo: 40 mg mannitol in 0.5 mL of solution.\n\nDosing: 0, 1, 3, 6, 9, 12, 15, 18, 21, 24 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "233"}, {"groupId": "OG001", "value": "235"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "63", "lowerLimit": "57", "upperLimit": "69"}, {"groupId": "OG001", "value": "57", "lowerLimit": "50", "upperLimit": "63"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.44", "pValueComment": "The a priori threshold for statistical significance was 0.05", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "The MMRM model was adjusted for the following covariates: age, Baseline C-peptide, Baseline insulin dose adjusted for body weight, and Baseline AUC", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Frequency of Hypoglycemic Events", "description": "Total number of days with at least one hypoglycemic event recorded", "populationDescription": "Full Analysis Set (FAS) All subjects randomized who had a baseline visit and at least one scheduled post-baseline visit", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "days", "timeFrame": "Baseline to 25 Months", "groups": [{"id": "OG000", "title": "DiaPep277", "description": "Administration of 1 mg DiaPep277\u00ae, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.\n\nDiaPep277: 1.0 mg dose in 0.5 mL of solution"}, {"id": "OG001", "title": "Placebo", "description": "Administration of placebo, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.\n\nPlacebo: 40 mg mannitol in 0.5 mL of solution.\n\nDosing: 0, 1, 3, 6, 9, 12, 15, 18, 21, 24 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "233"}, {"groupId": "OG001", "value": "235"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1955"}, {"groupId": "OG001", "value": "3264"}]}]}]}, {"type": "SECONDARY", "title": "Mean Number of Days With at Least One Hypoglycemic Event", "populationDescription": "Full Analysis Set (FAS) All subjects randomized who had a baseline visit and at least one scheduled post-baseline visit", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "days", "timeFrame": "Baseline to 25 months", "groups": [{"id": "OG000", "title": "DiaPep277", "description": "Administration of 1 mg DiaPep277\u00ae, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.\n\nDiaPep277: 1.0 mg dose in 0.5 mL of solution"}, {"id": "OG001", "title": "Placebo", "description": "Administration of placebo, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.\n\nPlacebo: 40 mg mannitol in 0.5 mL of solution.\n\nDosing: 0, 1, 3, 6, 9, 12, 15, 18, 21, 24 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "233"}, {"groupId": "OG001", "value": "235"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13.0", "spread": "2.3"}, {"groupId": "OG001", "value": "35.4", "spread": "7.6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The number of hypoglycemia events during the study was analyzed using a negative binomial regression model, with number of events as the dependent variable, and treatment, age, baseline daily insulin dose, and baseline C-peptide as covariates. The log of duration in the study for each patient was used as an offset variable in the model.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.07", "pValueComment": "Standard multiple imputation was used to predict the number and timing of hypoglycemic events after discontinuing the study for subjects who did not remain in the study until Month 25.", "statisticalMethod": "negative binomial regression", "paramType": "Hazard Ratio (HR)", "paramValue": "0.38", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.02", "ciUpperLimit": "0.79"}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "timeFrame": "AE data were collected from the time of subject enrollment through one month after the final product administrations (Total of 25 months after first study product administration)", "eventGroups": [{"id": "EG000", "title": "DiaPep277", "description": "Administration of 1 mg DiaPep277\u00ae, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.\n\nDiaPep277: 1.0 mg dose in 0.5 mL of solution", "seriousNumAffected": 15, "seriousNumAtRisk": 236, "otherNumAffected": 171, "otherNumAtRisk": 236}, {"id": "EG001", "title": "Placebo", "description": "Administration of placebo, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.\n\nPlacebo: 40 mg mannitol in 0.5 mL of solution.\n\nDosing: 0, 1, 3, 6, 9, 12, 15, 18, 21, 24 months", "seriousNumAffected": 10, "seriousNumAtRisk": 238, "otherNumAffected": 172, "otherNumAtRisk": 238}], "seriousEvents": [{"term": "Diabetic ketoacidosis", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 238}]}, {"term": "Hypoglycemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 238}]}, {"term": "Diabetes mellitus inadequate control", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 238}]}, {"term": "Meningitis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 238}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 238}]}, {"term": "Tick-borne viral encephalitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 238}]}, {"term": "Tonsillitis Streptococcal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 238}]}, {"term": "Sialoadenitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 238}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 238}]}, {"term": "Duodenal ulcer hemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 238}]}, {"term": "Incarcerated inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 238}]}, {"term": "Anal fistula", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 238}]}, {"term": "Meniscus inury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 238}]}, {"term": "multiple injuries", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 238}]}, {"term": "Muscle disorder", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 238}]}, {"term": "Sympathetic posterior cervical syndrome", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 238}]}, {"term": "Hypoglycemic seizure", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 238}]}, {"term": "Loss of Consciousness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 238}]}, {"term": "Lymphadenitis", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 238}]}, {"term": "Benign muscle neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 238}]}, {"term": "Abortion spontaneous", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 238}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 238}]}, {"term": "Nasal septum deviation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 238}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 52, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 60, "numAtRisk": 238}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 18, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 238}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 17, "numAtRisk": 238}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 238}]}, {"term": "Gastroenteriitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 238}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 238}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 238}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 238}]}, {"term": "Tonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 238}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 238}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 238}]}, {"term": "Diarrhea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 238}]}, {"term": "Abdominal Pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 238}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 238}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 238}]}, {"term": "vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 238}]}, {"term": "Injection site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 20, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 18, "numAtRisk": 238}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 238}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 238}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 25, "numAtRisk": 238}]}, {"term": "Migraine", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 238}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 238}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 238}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 238}]}, {"term": "Laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 238}]}, {"term": "Joint injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 238}]}, {"term": "Blood creatine phosphokinase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 238}]}, {"term": "Blood thyroid stimulating hormone increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 238}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 238}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 238}]}, {"term": "Respiratory disorder", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 238}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 238}]}, {"term": "Hypercholesterolemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 238}]}, {"term": "Psychiatric disorders", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 238}]}, {"term": "Blood and lymphatic system disorders", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 238}]}, {"term": "Cardiac disorders", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 238}]}, {"term": "Hypothyroidism", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 238}]}, {"term": "Immune system disorders", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 238}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 238}]}, {"term": "Renal and urinary disorders", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 238}]}, {"term": "Eye disorders", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 238}]}, {"term": "Reproductive system and breast disorders", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 238}]}, {"term": "Hepatobiliary Disorders", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 236}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 238}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Investigator shall submit any paper or presentation to the Sponsor for review and comments at least 60 days prior to submitting the same to a third party. Upon receiving any request from the Sponsor to delete any Confidential Information or request to delay in publication up to 90 days to allow the filing of any Sponsor application, the Investigator shall take the request action. Investigator shall not be restricted after 18 months from completion of their site's performance in the study."}, "pointOfContact": {"title": "Dr. Jeanne Novak", "organization": "CBR International", "email": "jnovak@cbrintl.com", "phone": "7207461190"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003922", "term": "Diabetes Mellitus, Type 1"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}, {"id": "D000001327", "term": "Autoimmune Diseases"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7117", "name": "Diabetes Mellitus, Type 1", "asFound": "Type 1 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}, {"id": "M4629", "name": "Autoimmune Diseases", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M21860", "name": "Pharmaceutical Solutions", "relevance": "LOW"}, {"id": "M11342", "name": "Mannitol", "relevance": "LOW"}], "browseBranches": [{"abbrev": "PhSol", "name": "Pharmaceutical Solutions"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}]}}, "hasResults": true}